The degree of oxidized cysteine (Cys) 34 in human serum albumin (HSA), as determined by high performance liquid chromatography (HPLC), is correlated with oxidative stress related pathological conditions. In order to further characterize the oxidation of Cys34-HSA at the molecular level and to develop a suitable analytical method for a rapid and sensitive clinical laboratory analysis, the use of electrospray ionization time-of-flight mass spectrometer (ESI-TOFMS) was evaluated. A marked increase in the cysteinylation of Cys34 occurs in chronic liver and kidney diseases and diabetes mellitus. A significant positive correlation was observed between the Cys-Cys34-HSA fraction of plasma samples obtained from 229 patients, as determined by ESI-TOFMS, and the degree of oxidized Cys34-HSA determined by HPLC. The Cys-Cys34-HSA fraction was significantly increased with the progression of liver cirrhosis, and was reduced by branched chain amino acids (BCAA) treatment. The changes in the Cys-Cys34-HSA fraction were significantly correlated with the alternations of the plasma levels of advanced oxidized protein products, an oxidative stress marker for proteins. The binding ability of endogenous substances (bilirubin and tryptophan) and drugs (warfarin and diazepam) to HSA purified from chronic liver disease patients were significantly suppressed but significantly improved by BCAA supplementation. Interestingly, the changes in this physiological function of HSA in chronic liver disease were correlated with the Cys-Cys34-HSA fraction. In conclusion, ESI-TOFMS is a suitable high throughput method for the rapid and sensitive quantification of Cys-Cys34-HSA in a large number of samples for evaluating oxidative stress related chronic disease progression or in response to a treatment.
References
[1]
Association AD (2013) Diagnosis and classification of diabetes mellitus. Diabetes Care 36 Suppl 1S67–74.
[2]
Furusyo N, Hayashi J (2013) Glycated albumin and diabetes mellitus. Biochim Biophys Acta.
[3]
Poli G (2000) Pathogenesis of liver fibrosis: role of oxidative stress. Mol Aspects Med 21: 49–98.
[4]
Descamps-Latscha B, Witko-Sarsat V (2001) Importance of oxidatively modified proteins in chronic renal failure. Kidney Int Suppl 78: S108–113.
[5]
Pergola PE, Raskin P, Toto RD, Meyer CJ, Huff JW, et al. (2011) Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365: 327–336.
[6]
Sogami M, Era S, Nagaoka S, Kuwata K, Kida K, et al. (1985) High-performance liquid chromatographic studies on non-mercapt in equilibrium with mercapt conversion of human serum albumin. II. J Chromatogr 332: 19–27.
[7]
Terawaki H, Yoshimura K, Hasegawa T, Matsuyama Y, Negawa T, et al. (2004) Oxidative stress is enhanced in correlation with renal dysfunction: examination with the redox state of albumin. Kidney Int 66: 1988–1993.
[8]
Anraku M, Kitamura K, Shinohara A, Adachi M, Suenga A, et al. (2004) Intravenous iron administration induces oxidation of serum albumin in hemodialysis patients. Kidney Int 66: 841–848.
[9]
Anraku M, Kitamura K, Shintomo R, Takeuchi K, Ikeda H, et al. (2008) Effect of intravenous iron administration frequency on AOPP and inflammatory biomarkers in chronic hemodialysis patients: a pilot study. Clin Biochem 41: 1168–1174.
[10]
Shimoishi K, Anraku M, Kitamura K, Tasaki Y, Taguchi K, et al. (2007) An oral adsorbent, AST-120 protects against the progression of oxidative stress by reducing the accumulation of indoxyl sulfate in the systemic circulation in renal failure. Pharm Res 24: 1283–1289.
[11]
Kadowaki D, Anraku M, Tasaki Y, Kitamura K, Wakamatsu S, et al. (2007) Effect of olmesartan on oxidative stress in hemodialysis patients. Hypertens Res 30: 395–402.
[12]
Yamasaki K, Chuang VT, Maruyama T, Otagiri M (2013) Albumin-drug interaction and its clinical implication. Biochim Biophys Acta.
[13]
Sengupta S, Chen H, Togawa T, DiBello PM, Majors AK, et al. (2001) Albumin thiolate anion is an intermediate in the formation of albumin-S-S-homocysteine. J Biol Chem 276: 30111–30117.
[14]
Alvarez B, Carballal S, Turell L, Radi R (2010) Formation and reactions of sulfenic acid in human serum albumin. Methods Enzymol 473: 117–136.
[15]
Oettl K, Stauber RE (2007) Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties. Br J Pharmacol 151: 580–590.
[16]
Narazaki R, Otagiri M (1997) Covalent binding of a bucillamine derivative with albumin in sera from healthy subjects and patients with various diseases. Pharm Res 14: 351–353.
[17]
Kawakami A, Kubota K, Yamada N, Tagami U, Takehana K, et al. (2006) Identification and characterization of oxidized human serum albumin. A slight structural change impairs its ligand-binding and antioxidant functions. FEBS J 273: 3346–3357.
[18]
Kubota K, Nakayama A, Takehana K, Kawakami A, Yamada N, et al. (2009) A simple stabilization method of reduced albumin in blood and plasma for the reduced/oxidized albumin ratio measurement. Int J Biomed Sci 5: 293–301.
[19]
Regazzoni L, Del Vecchio L, Altomare A, Yeum KJ, Cusi D, et al. (2013) Human serum albumin cysteinylation is increased in end stage renal disease patients and reduced by hemodialysis: mass spectrometry studies. Free Radic Res 47: 172–180.
[20]
Boisvert MR, Koski KG, Skinner CD (2010) Increased oxidative modifications of amniotic fluid albumin in pregnancies associated with gestational diabetes mellitus. Anal Chem 82: 1133–1137.
[21]
Mera K, Anraku M, Kitamura K, Nakajou K, Maruyama T, et al. (2005) The structure and function of oxidized albumin in hemodialysis patients: Its role in elevated oxidative stress via neutrophil burst. Biochem Biophys Res Commun 334: 1322–1328.
[22]
Jagannathan V, March C, Venitz J (1995) Determination of unbound L-tryptophan in human plasma using high-performance liquid chromatography with fluorescence detection. Biomed Chromatogr 9: 305–308.
[23]
Mera K, Takeo K, Izumi M, Maruyama T, Nagai R, et al. (2010) Effect of reactive-aldehydes on the modification and dysfunction of human serum albumin. J Pharm Sci 99: 1614–1625.
[24]
Watanabe H, Tanase S, Nakajou K, Maruyama T, Kragh-Hansen U, et al. (2000) Role of arg-410 and tyr-411 in human serum albumin for ligand binding and esterase-like activity. Biochem J 349 Pt 3: 813–819.
[25]
Minomo A, Ishima Y, Kragh-Hansen U, Chuang VT, Uchida M, et al. (2011) Biological characteristics of two lysines on human serum albumin in the high-affinity binding of 4Z,15Z-bilirubin-IXα revealed by phage display. FEBS J 278: 4100–4111.
[26]
Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, Nguyen-Khoa T, Nguyen AT, et al. (1996) Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49: 1304–1313.
[27]
Borges CR, Oran PE, Buddi S, Jarvis JW, Schaab MR, et al. (2011) Building multidimensional biomarker views of type 2 diabetes on the basis of protein microheterogeneity. Clin Chem 57: 719–728.
[28]
Musante L, Candiano G, Petretto A, Bruschi M, Dimasi N, et al. (2007) Active focal segmental glomerulosclerosis is associated with massive oxidation of plasma albumin. J Am Soc Nephrol 18: 799–810.
[29]
Carballal S, Radi R, Kirk MC, Barnes S, Freeman BA, et al. (2003) Sulfenic acid formation in human serum albumin by hydrogen peroxide and peroxynitrite. Biochemistry 42: 9906–9914.
[30]
Anraku M, Chuang VT, Maruyama T, Otagiri M (2013) Redox properties of serum albumin. Biochim Biophys Acta.
[31]
Jalan R, Schnurr K, Mookerjee RP, Sen S, Cheshire L, et al. (2009) Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology 50: 555–564.
[32]
Oettl K, Birner-Gruenberger R, Spindelboeck W, Stueger HP, Dorn L, et al. (2013) Oxidative Albumin Damage in Chronic Liver Failure: Relation to Albumin Binding Capacity, Liver Dysfunction and Survival. J Hepatol.
[33]
Takikawa H, Sugiyama Y, Hanano M, Kurita M, Yoshida H, et al. (1987) A novel binding site for bile acids on human serum albumin. Biochim Biophys Acta 926: 145–153.
[34]
Kawaguchi T, Izumi N, Charlton MR, Sata M (2011) Branched-chain amino acids as pharmacological nutrients in chronic liver disease. Hepatology 54: 1063–1070.
[35]
Nishitani S, Ijichi C, Takehana K, Fujitani S, Sonaka I (2004) Pharmacological activities of branched-chain amino acids: specificity of tissue and signal transduction. Biochem Biophys Res Commun 313: 387–389.
[36]
Kuwahata M, Yoshimura T, Sawai Y, Amano S, Tomoe Y, et al. (2008) Localization of polypyrimidine-tract-binding protein is involved in the regulation of albumin synthesis by branched-chain amino acids in HepG2 cells. J Nutr Biochem 19: 438–447.
[37]
Ichikawa K, Okabayashi T, Shima Y, Iiyama T, Takezaki Y, et al. (2012) Branched-chain amino acid-enriched nutrients stimulate antioxidant DNA repair in a rat model of liver injury induced by carbon tetrachloride. Mol Biol Rep 39: 10803–10810.
[38]
Terawaki H, Matsuyama Y, Matsuo N, Ogura M, Mitome J, et al. (2012) A lower level of reduced albumin induces serious cardiovascular incidence among peritoneal dialysis patients. Clin Exp Nephrol 16: 629–635.
[39]
Iwao Y, Ishima Y, Yamada J, Noguchi T, Kragh-Hansen U, et al. (2012) Quantitative evaluation of the role of cysteine and methionine residues in the antioxidant activity of human serum albumin using recombinant mutants. IUBMB Life 64: 450–454.
[40]
Anraku M, Takeuchi K, Watanabe H, Kadowaki D, Kitamura K, et al. (2011) Quantitative analysis of cysteine-34 on the anitioxidative properties of human serum albumin in hemodialysis patients. J Pharm Sci 100: 3968–3976.
